663 related articles for article (PubMed ID: 21719095)
21. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
von Herrath M; Bain SC; Bode B; Clausen JO; Coppieters K; Gaysina L; Gumprecht J; Hansen TK; Mathieu C; Morales C; Mosenzon O; Segel S; Tsoukas G; Pieber TR;
Lancet Diabetes Endocrinol; 2021 Apr; 9(4):212-224. PubMed ID: 33662334
[TBL] [Abstract][Full Text] [Related]
22. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
[TBL] [Abstract][Full Text] [Related]
23. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
[TBL] [Abstract][Full Text] [Related]
24. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of Teplizumab for Treatment of Type One Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Nourelden AZ; Elshanbary AA; El-Sherif L; Benmelouka AY; Rohim HI; Helmy SK; Sayed MK; Ismail A; Ali AS; Ragab KM; Zaazouee MS
Endocr Metab Immune Disord Drug Targets; 2021; 21(10):1895-1904. PubMed ID: 33302842
[TBL] [Abstract][Full Text] [Related]
26. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
Diamant M; Van Gaal L; Stranks S; Northrup J; Cao D; Taylor K; Trautmann M
Lancet; 2010 Jun; 375(9733):2234-43. PubMed ID: 20609969
[TBL] [Abstract][Full Text] [Related]
27. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Heller S; Buse J; Fisher M; Garg S; Marre M; Merker L; Renard E; Russell-Jones D; Philotheou A; Francisco AM; Pei H; Bode B;
Lancet; 2012 Apr; 379(9825):1489-97. PubMed ID: 22521071
[TBL] [Abstract][Full Text] [Related]
28. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.
Gitelman SE; Gottlieb PA; Felner EI; Willi SM; Fisher LK; Moran A; Gottschalk M; Moore WV; Pinckney A; Keyes-Elstein L; Harris KM; Kanaparthi S; Phippard D; Ding L; Bluestone JA; Ehlers MR;
Diabetologia; 2016 Jun; 59(6):1153-61. PubMed ID: 27053235
[TBL] [Abstract][Full Text] [Related]
29. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
[TBL] [Abstract][Full Text] [Related]
30. Teplizumab for treatment of type 1 diabetes mellitus.
Skelley JW; Elmore LK; Kyle JA
Ann Pharmacother; 2012 Oct; 46(10):1405-12. PubMed ID: 22968521
[TBL] [Abstract][Full Text] [Related]
31. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
[TBL] [Abstract][Full Text] [Related]
32. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
[TBL] [Abstract][Full Text] [Related]
33. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
Herold KC; Gitelman SE; Masharani U; Hagopian W; Bisikirska B; Donaldson D; Rother K; Diamond B; Harlan DM; Bluestone JA
Diabetes; 2005 Jun; 54(6):1763-9. PubMed ID: 15919798
[TBL] [Abstract][Full Text] [Related]
34. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Bailey CJ; Gross JL; Pieters A; Bastien A; List JF
Lancet; 2010 Jun; 375(9733):2223-33. PubMed ID: 20609968
[TBL] [Abstract][Full Text] [Related]
35. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial.
Bolinder J; Antuna R; Geelhoed-Duijvestijn P; Kröger J; Weitgasser R
Lancet; 2016 Nov; 388(10057):2254-2263. PubMed ID: 27634581
[TBL] [Abstract][Full Text] [Related]
36. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
37. Immune therapy and β-cell death in type 1 diabetes.
Lebastchi J; Deng S; Lebastchi AH; Beshar I; Gitelman S; Willi S; Gottlieb P; Akirav EM; Bluestone JA; Herold KC
Diabetes; 2013 May; 62(5):1676-80. PubMed ID: 23423576
[TBL] [Abstract][Full Text] [Related]
38. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Keymeulen B; Vandemeulebroucke E; Ziegler AG; Mathieu C; Kaufman L; Hale G; Gorus F; Goldman M; Walter M; Candon S; Schandene L; Crenier L; De Block C; Seigneurin JM; De Pauw P; Pierard D; Weets I; Rebello P; Bird P; Berrie E; Frewin M; Waldmann H; Bach JF; Pipeleers D; Chatenoud L
N Engl J Med; 2005 Jun; 352(25):2598-608. PubMed ID: 15972866
[TBL] [Abstract][Full Text] [Related]
39. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial.
Carlsson PO; Espes D; Sisay S; Davies LC; Smith CIE; Svahn MG
Diabetologia; 2023 Aug; 66(8):1431-1441. PubMed ID: 37221247
[TBL] [Abstract][Full Text] [Related]
40. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
